Wordt geladen...
Pharmacovigilance Considerations for Biosimilars in the USA
In 2015, five or more biosimilars may be approved in the USA. Because no two biologic medicines are identical, postapproval safety monitoring will be critical to detect potential differences in safety signals between a biosimilar, its reference product, and other biosimilars. Postapproval safety mon...
Bewaard in:
| Gepubliceerd in: | BioDrugs |
|---|---|
| Hoofdauteurs: | , |
| Formaat: | Artigo |
| Taal: | Inglês |
| Gepubliceerd in: |
Springer International Publishing
2015
|
| Onderwerpen: | |
| Online toegang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4626527/ https://ncbi.nlm.nih.gov/pubmed/26419971 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s40259-015-0137-2 |
| Tags: |
Voeg label toe
Geen labels, Wees de eerste die dit record labelt!
|